Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sol-Gel Technologies Ltd. SLGL
$3.42
+$0.04 (1.04%)
На 18:00, 12 мая 2023
+514.04%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
90448160.00000000
-
week52high
6.89
-
week52low
3.24
-
Revenue
3883000
-
P/E TTM
-7
-
Beta
1.29169500
-
EPS
-0.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Strong Buy | Strong Buy | 16 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 25 апр 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 01 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2021 г. |
| Raymond James | Strong Buy | Strong Buy | 12 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 29 авг 2022 г. |
| Jefferies | Hold | 21 окт 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 14 ноя 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 11 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
12 мая 2023 г. в 09:56
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewsWire
20 мар 2023 г. в 07:00
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright's Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.
7 Biotech Stocks That Could Be the Next Big Thing
InvestorPlace
15 мар 2023 г. в 11:44
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
10 мар 2023 г. в 09:57
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.
The Top 7 Penny Stocks to Invest in for the Long-Term
InvestorPlace
23 февр 2023 г. в 14:32
Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investment.